The Relevance of Plasma Lipid Changes with Cardiovascular Drug Therapy

Johnson, Brian F. G.; Danylchuk, Margaret A.

doi:10.1016/s0025-7125(16)30682-4

Cited by 28 publications

(4 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…94 This effect is seen with oral carteolol. 110 Timolol, in contrast, increases triglycerides by 12% and decreases HDL cholesterol by 9%. 111 Studies comparing topical carteolol to timolol showed carteolol to be neutral in its effect on serum lipid levels, whereas timolol maleate adaversely affects the HDL, total cholesterol, and total cholesterol/HDL ration.…”

Section: Metipranololmentioning

confidence: 99%

Cardiovascular and Respiratory Considerations With Pharmacotherapy of Glaucoma and Ocular Hypertension

Han¹,

Frishman²,

Sun³

et al. 2008

Cardiology in Review

View full text Add to dashboard Cite

Glaucoma and ocular hypertension are highly prevalent conditions in individuals over the age of 40 and are commonly seen together in patients with cardiovascular disease. Many of the antiglaucoma medications, when systemically absorbed, affect the sympathetic and parasympathetic nervous systems of patients and can cause cardiovascular toxicity. Such adverse effects are frequently associated with the long-term use of potentially toxic agents in elderly people, who are most prone to chronic eye disease. Moreover, patients may not associate their symptoms with the topical eye medications, and consequently may not report adverse drug effects. Drug-drug interactions can also occur when patients are taking medications for both cardiovascular disease and glaucoma. In this review, the systemic toxicity of these agents is reviewed, along with possible drug-drug interactions. Mention is made of other antiglaucoma medications used alone and in combination with topical beta-blockers. Identification of genetic loci-a bold new step toward glaucoma treatment-is mentioned briefly at the end of the article.

show abstract

Section: Metipranololmentioning

confidence: 99%

Cardiovascular and Respiratory Considerations With Pharmacotherapy of Glaucoma and Ocular Hypertension

Han¹,

Frishman²,

Sun³

et al. 2008

Cardiology in Review

View full text Add to dashboard Cite

show abstract

“…However, it has been suggested that these side effects are mediated via ancillary receptors (Reid et al, 1983) so that a drug with increased selectivity for a2-adrenoceptors would be less likely to cause sedation and somnolence. The development of a centrally acting antihypertensive agent possessing truly differential effects on blood pressure and sedation might be of considerable clinical relevance since this class of drug is both effective and without deleterious metabolic effects (Johnson & Danylchuk, 1989;Lardinois & Neumann, 1988).…”

Section: Introductionmentioning

confidence: 99%

A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects.

Macphee

Howie

Elliott

et al. 1992

Brit J Clinical Pharma

View full text Add to dashboard Cite

“…β‐blockers and diuretics are associated with metabolic effects that may offset the benefits of blood pressure reduction. These drugs may also have adverse effects on insulin resistance, contributing to the risk of developing diabetes 20–34 . In comparison, CCBs and ACE inhibitors are generally associated with neutral metabolic effects, although some studies have reported improvements in insulin sensitivity with ACE inhibitors 35–37 .…”

Section: Considerations For Antihypertensive Therapymentioning

confidence: 99%

Considerations for Drug Therapy in Hypertension

McNally

2001

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYBoth the Joint National Committee and the British Hypertension Society recommend b‐blockers and diuretics as first‐line therapy in the treatment of uncomplicated hypertension. As a result, many clinicians will also prescribe these drugs in the treatment of patients with hypertension and coexistent disease (unless they are specifically contraindicated), even though they may not always be the most beneficial choice. This review aims to examine factors that should be taken into consideration when choosing appropriate antihypertensive therapy. Particular attention is given to treatment options in two special patient groups, the elderly and patients with co‐morbid diabetes, as these groups have an increased risk of developing cardiovascular complications. In response to the increasing evidence base from large‐scale trials, the article concludes that cardiovascular risk factors, coexisting disease, concomitant medication and age should all be taken into account when choosing antihypertensive therapy.

show abstract

The Relevance of Plasma Lipid Changes with Cardiovascular Drug Therapy

Cited by 28 publications

References 108 publications

Cardiovascular and Respiratory Considerations With Pharmacotherapy of Glaucoma and Ocular Hypertension

Cardiovascular and Respiratory Considerations With Pharmacotherapy of Glaucoma and Ocular Hypertension

A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects.

Considerations for Drug Therapy in Hypertension

Contact Info

Product

Resources

About